Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me

Stanley Capital has announced the acquisition of MyMeds&Me by its portfolio company Drug Safety and Pharmacovigilance Services Solutions.

Stanley Capital Partners (SCP), a European and US-focused mid-market private equity firm, announced on April 4, 2022 that it has acquired MyMeds&Me (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a global pharmacovigilance service under the brand Bioclinica.

MyMeds&Me captures safety data directly from patients, healthcare professionals, and pharma teams through its global SaaS platform, Reportum. MMM’s global client base includes some of the world’s leading pharmaceutical companies.

The digital-first approach will enable DSS to be a foremost provider of pharmacovigilance services, leveraging Reportum for the capture and management of relevant data. The approach will also allow for the accelerated development of the Reportum platform’s capabilities and its integration into the technology landscape.

“The acquisition of MMM will give a further boost to the high-quality service offering we are delivering to our clients, which include some of the world’s largest and most innovative pharmaceutical companies, with the support and investment of SCP,” said Humaira Qureshi, CEO of DSS, in a press release. “The acquisition aligns with the shared strategy of DSS and SCP to secure M&A transactions that grow the technology-enabled platform and broaden the client-focused service offering.”

“MyMeds&Me is proud to be joining the DSS family, providing us with a framework to expand our high-quality technology offering,” said Dr Andrew Rut, CEO and founder of MMM, in a press release. “With the industry’s ever greater focus on patient engagement, the deployment of innovative technology combined with complementary services from DSS will enable our customers to revolutionize their pharmacovigilance strategy and optimize the safe use of their medicines.”
Source: MyMeds&Me